The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
DW
极限001
aaaa
aaa
xing_xing
意肆
lx
invisight
aajhajkahna
maxiaole
CR7
KWang
乐空思
碧海蓝天
Mic
初景
花开富贵
坚强冰枫
优雅的从安
皖公网安备34019202002308
